EVKEEZA (evinacumab-dgnb)

Medical Administration - intravenous

Diagnosis considered for coverage:
  • Indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH).
Limitations of Use:
  • The safety and effectiveness of Evkeeza™ have not been established in patients with other causes of hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). The effects of Evkeeza™ on cardiovascular morbidity and mortality have not been determined.
Coverage Criteria:

For diagnosis of Homozygous Familial Hypercholesterolemia (HoFH):

  • Dose does not exceed 15 milligrams per kilogram of bodyweight infused once every 4 weeks, AND
  • Patient is 12 years of age or older, AND
  • Prescribed by a cardiologist, endocrinologist, or lipid specialist, AND
  • Medical records (e.g., chart notes, laboratory values) document diagnosis of homozygous familial hypercholesterolemia (HoFH) as confirmed by one of the following:
    • Genetic confirmation of two mutant alleles at the LDLR, APOB, PCSK9, or LDLRAP1 gene locus, OR
    • Both of the following:
      • One of the following:
        • Untreated/pre-treatment LDL-C greater than 500 mg/dL
        • Treated LDL-C greater than 300 mg/dL
      • One of the following:
        • Xanthoma before 10 years of age
        • Evidence of heterozygous familial hypercholesterolemia in both parents
  • Patient has failed to achieve a low-density lipoprotein-cholesterol (LDL-C) goal of less than 100 mg/dL (or 70 mg/dL in HoFH patients with clinical cardiovascular disease (CVD)) (recent lab documentation required) despite the use of both of the following:
    • One of the following:
      • Patient is currently treated with maximally tolerated statin therapy plus ezetimibe, OR
      • Patient is unable to tolerate statin therapy as evidenced by one of the following intolerable and persistent (i.e., more than 2 weeks) symptoms
        • Myalgia (muscle symptoms without CK elevations)
        • Myositis (muscle symptoms with CK elevations less than 10 times upper limit of normal [ULN]), OR
      • Patient has a labeled contraindication to all statins as documented in medical records, OR
      • Patient has experienced rhabdomyolysis or muscle symptoms with statin treatment with CK elevations greater than 10 times ULN, AND
    • One of the following:
      • Patient has been treated with PCSK9 therapy or did not respond to PCSK9 therapy
      • Physician attests that the patient is known to have two LDL-receptor negative alleles (little to no residual function) and therefore would not respond to PCSK9 therapy
      • Patient has a history of intolerance or contraindication to PCSK9 therapy
      • Patient has previously been treated with Juxtapid® (lomitapide)
      • Patient has previously been treated with lipoprotein apheresis, AND
  • Patient will continue other traditional lipid-lowering therapies (e.g., maximally tolerated statins, ezetimibe) in combination with Evkeeza™
Reauthorization Criteria:

For diagnosis of Homozygous Familial Hypercholesterolemia (HoFH):

  • Dose does not exceed 15 milligrams per kilogram of bodyweight infused once every 4 weeks, AND
  • Prescribed by a cardiologist, endocrinologist or lipid specialist, AND
  • Medical records (e.g., chart notes, laboratory values) document LDL-C reduction while on Evkeeza™ therapy, AND
  • Patient will continue other traditional lipid-lowering therapies (e.g., maximally tolerated statins, ezetimibe) in combination with Evkeeza™
Coverage Duration:
  • Initial: 6 months
  • Reauthorization: 1 year
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information:
  • Warnings and precautions include embryo-fetal toxicity.  Based on the findings in animal reproduction studies, Evkeeza™ may cause fetal harm when administered to pregnant patients.  Advise patients who may become pregnant of the risk to a fetus.  Consider obtaining a pregnancy test prior to initiating treatment with Evkeeza™.  Advise patients who may become pregnant to use effective contraception during treatment with Evkeeza™ and for at least 5 months following the last dose of Evkeeza™.  
Policy Updates:
  • 6/15/2021 – New policy approved by P&T.
References:
  • Evkeeza Prescribing Information. Regeneron Pharmaceuticals, Inc. Tarrytown, NY. February 2021.
  • Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711-720. doi:10.1056/NEJMoa2004215
  • Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223:262-8.
  • Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35:2146-57.
  • Harada-Shiba M, Arai H, Ishigaki Y, et al. Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017. J Atheroscler Thromb. 2018;25(8):751-770. doi:10.5551/jat.CR003
  • Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73:e285-e350.
  • Rosenson RS, Durrington PD. Familial hypercholesterolemia in adults: Treatment. UpToDate. http://www.utdol.com. Updated September 14, 2020. Accessed March 26, 2021.
  • Adam RC, Mintah IJ, Alexa-Braun CA, et al. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. J Lipid Res. 2020;61(9):1271-1286. doi:10.1194/jlr.RA120000888
  • France M, Rees A, Datta D, et al. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis. 2016;255:128-139. doi:10.1016/j.atherosclerosis.2016.10.017

 

 

Last review date: June 15, 2021

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone